ESMO Asia 2023 – deaths raise doubts about Merus’s Rybrevant challenger
Merus still hopes for a future for MCLA-129, but the doors are closing.
Merus still hopes for a future for MCLA-129, but the doors are closing.
But, with the end in sight for the CD38 blockbuster, will Johnson & Johnson buy into Genmab’s next-gen project?
Keymed’s AstraZeneca-partnered anti-Claudin18.2 ADC looks better than Astellas’s zolbetuximab – albeit on an extremely unreliable metric.
A domvanalimab triplet shows some promise in high PD-L1-expressing gastric cancer patients, but caveats abound.
A 14% ORR with IDRX-42 in fourth-line GIST looks better than the 9% previously seen with Qinlock.
But the groups have yet to see any responses with AU-007 and XTX202 respectively.
Arcellx climbs 19%, but the most significant Car-T presentation at ASH might not even be in oncology.
The upcoming ASH conference will feature rival datasets from inhibitors of Menin, KIT, EZH1/2, BTK, BET, BCR/ABL and more.